首页> 外文期刊>BMC Health Services Research >Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
【24h】

Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?

机译:加拿大专利医学合规规定通知:平衡鳞片或划船它们吗?

获取原文
           

摘要

Background In order to comply with the provisions of the North American Free Trade Agreement, in 1993 the Canadian federal government introduced the Patented Medicine Notice of Compliance Linkage Regulations. These regulations were meant to achieve a balance between the timely entry of generic medicines and the rights of patent holders. The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product. Discussion Since their introduction the regulations have been a source of contention between the generic and the brand-name industry. While the regulations have generated a considerable amount of work for the Federal Court of Canada both sides dispute the interpretation of the "win rate" in the court cases. Similarly, there is no agreement on whether multiple patents on single drugs represent a legitimate activity by the brand-name industry or an "evergreening" tactic. The generic industry's position is that the regulations are being abused leading to the delay in the introduction of lower cost generic products by as much as 8 years. The brand-name companies counter that the regulations are necessary because injunctions against the introduction of generic products are frequently unavailable to them. The regulations were amended in 2006 and again in 2008 but both sides continue to claim that the regulations favour the other party. The battle around the regulations also has an international dimension with interventions by PhRMA, the trade association representing the United States based multinational companies, arguing that the regulations are not stringent enough and that Canada needs to be placed on the U.S. Priority Watch List of countries. Finally, there are multiple costs to Canadian society as a result of the NOC regulations. Summary Despite the rhetoric there has been almost no empiric academic research done into the effect of the regulations. In order to develop rational policy in this area a number of key research questions have been formulated.
机译:背景为遵守北美自由贸易协定的规定,1993年加拿大联邦政府介绍了合规联系法规的专利医学通知。这些规定旨在实现普通药物及专利持有人的权利之间的平衡。该法规将通用药物的监管批准与原始品牌产品的专利地位相关联。讨论以来他们引入法规是通用和名牌产业之间的争论来源。虽然法规为加拿大联邦法院产生了相当数量的工作,双方对法院案件中的“赢利”的解释。同样,没有关于单药对单项药物的多项专利代表品牌产业或“常青树”策略代表合法活动。通用行业的立场是,该法规被滥用导致延迟导致较低的成本通用产品的延迟多达8年。该品牌公司违反了该规定是必要的,因为对引入通用产品的禁令通常不可用。该法规于2006年及2008年再次修订,但双方继续宣称法规赞成另一方。围绕法规的战斗还有国际维度,这是由代表美国基于跨国公司的贸易协会的Phrma的国际方面,争论该法规不够严格,加拿大需要在美国优先观看国家名单上。最后,由于NOC法规,加拿大社会有多种成本。总结尽管有言论几乎没有经验的学术研究,以规定的影响。为了在这一领域制定理性的政策,已经制定了许多关键研究问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号